Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
15 hedge funds and large institutions have $1.17M invested in Better Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
2.72% less ownership
Funds ownership: 6.13% → 3.4% (-2.7%)
80% less capital inflows, than outflows
Capital inflows: $84.9K | Capital outflows: $428K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.5K |
| 2 |
Renaissance Technologies
New York
|
+$13K |
| 3 |
BlackRock
New York
|
+$8.92K |
| 4 |
Barclays
London,
United Kingdom
|
+$224 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$188 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Farallon Capital Management
San Francisco,
California
|
-$356K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34.6K |
| 3 |
Millennium Management
New York
|
-$19K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$11.4K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$4.21K |
BTTX Hedge Fund Activity: Q2 2023 in Review
15 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q2 2023, worth a combined $1.17M — up 12% from $1.04M a quarter earlier.
Fund positioning in BTTX was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $62.5K. The largest seller was Farallon Capital Management, cutting an estimated $356K.
- 15 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $1.17M of Better Therapeutics, Inc. Common Stock stock for Q2 2023, up 12% quarter-over-quarter.
- 3 funds opened new Better Therapeutics, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q2 2023 was Geode Capital Management, an estimated $62.5K added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q2 2023 was Farallon Capital Management, an estimated $356K sold.
Based on aggregated 13F filings for Q2 2023.